We have performed a retrospective analysis of the clinical, morphologic, and cytogenetic findings in 26 patients diagnosed between January 1969 and September 1991 with acute erythroblastic leukemia de novo (EL or AML-M6). Clonal chromosomal abnormalities were found in 20 (77%) patients (95% confidence interval [CI], 61% t o 93%). Loss of all or part of the long arm (4) of chromosomes 5 and/or 7 was observed in 17 (65%) patients (95% CI, 47% to 83%). In addition, the karyotypes were often complex, with multiple abnormalities and subclones. Among the remaining nine patients, six had a normal karyotype and one each had trisomy 8, t(3;3), or t(3;5). The overall frequency of abnormalities of chromosomes 5 and/or 7 observed in our M6 patients is similar t o that observed in our patients with therapyrelated acute myeloid leukemia (t-AML; 99 of 129 patients, 77%). but substantially higher than that noted in our other patients with AML de novo (French-American-British [FAB] subtypes Ml-M5: 52 of 334 patients, 16%). Our M6 patients CUTE ERYTHROBLASTIC leukemia (EL or AML-
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CUTE ERYTHROBLASTIC leukemia (EL or AML-
A M6) is a distinctive bone marrow (BM) disorder characterized by the neoplastic proliferation of erythroid and myeloid precursors.'-3 The erythroid precursors usually exhibit dyserythropoietic features. AML-M6 is relatively uncommon, comprising only 4% of de novo cases studied at the Fourth International Workshop on Chromosomes in L e~k e m i a .~ No specific cytogenetic abnormalities have been consistently identified in the relatively small number of M6 patients reported on thus far. In part, this has been due to the lack of uniform criteria for the subclassification of AML patients in the past. However, several investigators have reported that M6 has complex chromosomal aberrations and a poor prognosis. Nakamura5 reported on cytogenetic findings in 10 patients. Of the five patients with complex abnormalities in his study, four had abnormalities of chromosomes 5 and/or 7; a complete karyotype was provided for only one ~a t i e n t .~ Cuneo et a16 have recently reported on 20 patients with M6, but have included five patients who had secondary leukemia after exposure to cytotoxic therapy or irradiation. Fourteen of their patients had major karyotypic abnormalities, defined as the presence of three or more aberrations in the same clone, in addition to abnormalities of chromosomes 5 and/or 7. Complex karyotypes characterized by abnormalities of chromosomes 5 or 7 are commonly observed in the malignant cells from patients with therapy-related acute myeloid leukemia (t-AML), as well as in AML patients who have had occupational exposure to insecticides, solvents, chemicals, or petroleum prod~cts.~-l* However, a few patients with Ah4L de novo who lack a history of toxin exposure also have had abnormalities of chromosomes 5 and/or 7.4 Recurring chromosomal abnormalities have been shown to be an important prognostic factor in patients with AML de nov0. 12~13 In this study, we performed a retrospective analysis of all with abnormalities of chromosomes 5 and/or 7 were older and had a shorter median survival (16 v 77 weeks [P = .005])
than did the M6 patients without these abnormalities. We found no correlation between morphologic features and either cytogenetic abnormalities or clinical outcome. Of note was the finding that the percentage of myeloblasts, which may account for only a small fraction of the total marrow elements when the revised FA6 criteria are applied, had no bearing on prognosis. We conclude that acute erythroblastic leukemia, when defined by morphologic criteria, consists of two distinctive subgroups: one group tends t o be older, has complex cytogenetic abnormalities, especially of chromosomes 5 and/or 7, and shares biologic and clinical features with t-AML; the other group, with simple or no detectable cytogenetic abnormalities, has a more favorable prognosis when treated with intensive chemotherapy.
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patients with a diagnosis of M6 de novo whose marrow specimens were referred to our cytogenetics laboratory. We sought to determine (1) whether there were particular subsets of M6 patients that could be identified by distinctive clinical, morphologic, or cytogenetic characteristics; and (2) whether abnormalities of chromosomes 5 and/or 7 were consistently observed in a significant proportion of these patients. We have found that, within this morphologically defined subset of AML, there exist at least two cytogenetically distinct groups with different clinical features and outcomes.
OLOPADE ET AL MATERIALS AND METHODS
BM samples from patients referred to our laboratory for cytogenetic analysis between January 1969 and September 1991 with a diagnosis of "erythroleukemia" de novo were reviewed. None of these patients had received prior cytotoxic therapy or irradiation. Fifteen of the patients were diagnosed and managed as inpatients at the University of Chicago Medical Center or at an affiliated hospital. The remaining 11 patients were treated at other hospitals in the metropolitan Chicago area. The pretreatment BM biopsies and aspirate specimens and blood smears were reviewed by one of the investigators (J.W.V.). For a case to be included in this study, a BM aspirate smear obtained at the time of cytogenetic studies and before therapy had to be available for review. A 500-cell differential count was performed from the Wright'sstained BM aspirate, and each case was classified according to the criteria published by the French-American-British (FAB) Cooperative Study Group.2~~ Only those cases in which the erythroid precursors were 250% of all nucleated marrow cells and the myeloblasts were 2 30% of the nonerythroid cells were designated as M6. Peripheral blood (PB) smears and BM biopsy slides were available for review for most patients. Cytochemical and/or immunocytochemical studies were available for only 10 patients.
Cytogenetic analyses were performed with quinacrine fluorescence or trypsin-Giemsa banding techniques on BM cells from aspirates or biopsy specimens or on PB cells. Cells were examined from direct preparations, from 24-, 48-, or 72-hour unstimulated cultures, or from methotrexate-synchronized cells cultured for 48 hours with phytohemagglutinin-stimulated leukocyte-conditioned media. Chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomen~1ature.l~ Because this was a retrospective review, treatment was not uniform. Twenty-one patients received intensive remission induction chemotherapy with standard chemotherapy regimens designed to produce marrow hypoplasia, two patients received low-dose subcutaneous cytarabine, one received prednisone only, one patient refused therapy, and one patient died before treatment (Table 1) . Complete remission after induction chemotherapy was defined by the usual criteria of less than 5% blasts in a normocellular marrow with the PB showing normal blood counts (>1,500 granulocytes/pL and > 100,000 platelets/pL) without immature forms and lasting for more than 4 weeks.
End points were complete response rate (based only on 21 patients who had received intensive induction and consolidation) and overall survival. Survival duration was calculated from diagnosis to date of death or last patient contact. Life table estimates of survival were calculated using the method of Kaplan and Meier.Is The log-rank test was used to compare survival for the two cytogenetic subgroups. Both univariate and multivariate analyses were used for analysis of potential prognostic factors for survival. Univariate analyses and multivariate analyses of baseline hematologic variables and age were performed using Cox's proportional hazards regression analysis.16 The comparability of cytogenetic subgroups with regard to baseline variables was analyzed using the Mann-Whitney two-sample test.
Statistical methods.

RESULTS
Clinical features.
The clinical characteristics of the 26 patients are listed in Table 1 . Patients are numbered for this report; the unique patient numbers (UPNs) used to 
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Trilineage dysplasia was graded from 1 + to 4+ depending on of these (no. 13) did they account for more that 50% of the erythroid elements. A slide with the periodic acid-Schiff (PAS) reaction was available for review in only seven ( > 10%) were positive only in those cases with more than 30% pronormoblasts and basophilic normoblasts. Marked vacuolization of erythroid precursors was also limited to those cases with primarily immature erythroid precursors. The number of myeloid-morphology blasts ranged from 5% to 31% of the total marrow elements (but was greater than 30% of the nonerythroid cells in all cases). In all patients, trilineage dysplasia of variable degree was present. nent. Megakaryocytic dysplasia was frequently severe, with small and hypolobated megakaryocytes in 84% of the patients. Had the erythroid component been ignored, all except one case would have been morphologically classified as acute myelogenous leukemia with maturation (M2). The single exception (no. 19) showed a significant monocytic compoHistologic sections of biopsy specimens were available for 15 of the patients. Although in most cases there was a fairly uniform distribution of cell types in the biopsy, in three cases (nos. 11,17, and 23) there was markedly uneven localization of erythroid and granulocytic precursors. Although the aspirate smears from two of these patients showed differential counts that permitted them to be diagnosed as M6, marked differences in the percentage of erythroid precursors could be obtained from different sections of the biopsies. However, in one of these three patients (no. ll), erythroid cells, as determined from the aspirate, accounted for only 40% of the marrow elements; thus, the diagnosis of M6 was established from the biopsy specimen, which showed sheets of erythroid precursors occupying large regions of the biopsy sections and accounting for greater than 70% of the marrow elements. In this patient, the initial BM sample obtained at a local hospital before referral did show greater than 50% erythroid cells in the aspirate.
The results of cytogenetic analyses performed at diagnosis are shown in Table 3 . Clonal chromosomal abnormalities were detected in the leukemia cells from 20 (77%) patients (95% confidence interval [CI], 61% to 93%). In most patients, the majority of the metaphase cells were abnormal, and multiple subclones as well as complex abnormalities and unidentified marker chromosomes were common. In the samples with an abnormality, 27% to 95% of metaphase cells were abnormal. The number of abnormal clones was quite variable, ranging from 1 to 5, but all were related. Unidentified marker chromosomes (from 1 to 4) were seen in 10 patients. Three patients had simple clonal abnormalities: +8 (no. 20), t(3;3) (no. 19), and t(3;5) (no. 18). Five patients (nos. 22 through 26) had no abnormalities detected. We have also classified patient no. 21 as normal, although he had 13% of cells lacking a Y chromosome; we considered this within normal limits in a 76-year-old man.
Seventeen of 26 (65%) patients (95% CI, 47% to 83%) had clonal abnormalities leading to loss of the whole chromosome or part of the long arm of chromosome 5 [-5/de1(5q)] and/or chromosome 7 [-7/de1(7q)]. These data are summarized in Figs 2 and 3.
Sixteen patients had loss of the long arm of chromosome 5. As a primary change (ie, observed in the simplest clone), loss of the entire chromosome 5 was seen in one patient and loss of 5q was seen in 11; as a secondary change, -5 was seen in four other patients. Loss of material from 5q was due to interstitial deletion in nine patients and to unbalanced translocations in two others. Except for one patient (no. 6) who had a complex inversion of 5q and del(5p), all deletions included the region between 5q15 and 5q31. Eleven patients had loss of the long arm of chromosome 7 [-7 or del(7q)l. Loss of the entire chromosome was a primary change in three patients and a secondary change in four other patients. Loss of the long arm, seen in four patients, was always a primary change. It was the result of an unbalanced translocation in two patients, an interstitial deletion (7q22-q34) in one patient, and a ring chromosome (breaks in bands p2?2 and q3?1) in one other patient. The deleted segment in all patients included 7q31 to 7q34.
Ten patients had loss of at least some part of the long arms of both chromosomes 5 and 7. The most frequent
Cytogenetic features.
combination was -7 and del(5q) in five patients, followed by -5 and del(7q) or del(5q) with del(7q) each in two patients. A single patient had -5 and -7. Del(5q) and del(7p) were seen in three other patients. In three patients, it was possible to determine the order in which the abnormalities of 5 and 7 occurred, because the initial clone had an abnormality of only one of them. In patients no. 4 and 11, the del(5q) occurred before the -7; in patient no. 17, the reverse occurred, ie, an unbalanced translocation leading to loss of part of chromosome 7 ( p l l to qter) occurred before the -5. Aberrations of 5 and 7 were frequently present together in the simplest clone identified at diagnosis (6 patients). Aberrations of 5 and 7 were secondary to other changes in seven patients. These data suggest that even if a patient did not have an aberration of one of these chromosomes as the earliest event, loss of material from these chromosomes occurred relatively soon in the evolution of the neoplastic clone.
Among other aberrations, a gain of an entire chromosome 8 (trisomy) was observed in seven patients; in s k of the patients, it was present along with del(5q) and del(7q). It was the sole abnormality in one patient. A gain of only the short arm of chromosome 8 was observed in another patient in addition to del(5q) and del(7q). Another common aberration was a deletion of the short arm of chromosome 12 seen in six patients (nos. 1, 3, 4, 7, 9, and 10); all deletions included p12-pl3. Loss of an intact chromosome 12 was seen in three patients; in two patients, it was an early change. A deletion of the long arm of chromosome 16 was observed in five patients and always included bands q13 to q24. Loss of material from the long arm of chromosome 20 was observed in three patients either as a result of interstitial deletions or as a result of unbalanced translocations; part of band 20q13 (q13.1 to q13.3) was lost in every patient. Loss of an entire chromosome 17 or of part of its short arm was observed in two patients each; one of these patients (no. 7) had homozygous loss of 17p in a secondary clone.
Patient no. 10 had a completely different clonal abnormality in relapse compared with that at diagnosis. On two separate occasions (1 and 4 months after first relapse), 30% and 9% of cells had the karyotype 46,XX,idic( 18)(pll).
Three subgroups were identified by cytogenetic analysis. The first group included patients with major karyotypic abnormalities characterized by abnormalities of chromosomes 5 and/or 7, usually in association with other chromosomal abnormalities and with multiple subclones. The second group included patients with minor karyotypic abnormalities. The third group included patients with no detectable abnormalities (ie, normal karyotypes). In univariate analyses (data not shown), we could not detect any biologic or clinical differences between the second and third groups (probably due to low power because of the small sample sizes) and we therefore combined these two groups for further analyses.
Each patient's chemotherapy and response are listed in Table 1 . Thirteen of the 21 patients (62%) who received intensive chemotherapy achieved a complete remission (CR). Cytogenetic analysis was repeated on BM samples in 10 of the 13 patients in remission.
Response to therajy.
For (3;3)(p26;q21) ,+2der(5)t(l;5)(~22;ql l),+der (7) 80,XY,-X,-Y,-3,-4,-5,-5,-7,-13,-13,-13,-15,   45,XY,-6,de1(4)(q27l),del(5)(ql lql?3),del(6)(q2?l),de1(7)(pl?4),de1(8)(p2?l),del(9)(q3?1) , 46 ,XY, -1, -3, -5, -7, +8, -17, +der( 1 )t( 1 ;?9)(p34;q 13or21). +der (3) 7, the median survival was only 16 weeks, in contrast to the median survival of 77 weeks for the remaining nine patients (Fig 5; log-rank P = .005). There were no significant differences in basic hematologic values between the two groups, as shown in Table 4 . There was a trend towards a lower percentage of marrow blast cells in patients with abnormalities of chromosomes 5 and/or 7. Univariate survival analysis showed no correlation between survival and the fraction of marrow blast cells or PB blast cell count; however, age was found to show a correlation with survival (P = .009).
DISCUSSION
This report on 26 patients with AML-M6 de novo clarifies the type and frequency of chromosomal abnormalities in this relatively uncommon group of patients and confirms some observations of others. The higher frequency of loss of genetic material from the long arm of chromosome 5 relative to loss of chromosome 7 has not been commented on before. In our 26 patients, 16 (62%) and 11 (42%) had loss of chromosomes 5 and 7, respectively. 
H
Analysis of the data of Cuneo et a1,6 considering only the patients with M6 de novo, shows that nine (60%) and seven (47%) patients had loss of chromosomes 5 and 7, respectively. In both series, aberrations involving chromosome 5 occur more frequently than those involving chromosome 7. This is of interest for at least two reasons. The first reason is the well-established association of del(5q) with the myelodysplastic disorder refractory anemia, which has led to the assumption that one or more genes critical to red blood cell development are located on 5q. The second reason is related to t-AML, a syndrome to which the karyotypes in M6 are quite similar. In t-AML, aberrations of chromosomes 5 and 7 are common and the karyotypes are often very complex. However, the proportion of losses or deletions of 5q is higher in M6 (16 of 26 patients, 62%) than in t-AML patients (55 of 129 at the University of Chicago; Chromosome Number 43%), whereas the frequency of loss or deletion of 7q is lower in M6 (11 of 26,42%) compared with t-AML patients (73 of 129,57%). In contrast, in our concurrent series of 334 patients with AML de novo with subtypes M1 through M5, only 52 (16%) had abnormalities of chromosomes 5 and/or 7, and some of these patients had significant exposure through their occupation to potential mutagens. It is noteworthy that only five of the M6 patients in this study had a history suggestive of mutagen exposure, and three of them had normal karyotypes. More M6 patients will have to be analyzed before the consistency of the reversal in frequency (ie, loss of chromosome 5 greater than loss of chromosome 7) can be established. In any case, deletions of 5q and 7q are clearly important cytogenetic abnormalities in both M6 and in t-AML, as well as in certain myelodysplastic syndromes (MDS).4J0J7
The cytogenetic abnormalities observed in these 26 patients are similar to those described in the few M6 patients previously reported on in the literature. Using unbanded chromosomes, Sakurai and SandberglsJ9 identified major karyotypic abnormalities in 17 of 113 patients with AML; 8 of these 17 had M6. They proposed three groups of M6: those patients with normal karyotypes, those with minor karyotypic abnormalities, and those with major karyotypic abnormalities. As described above, all three groups are represented in our series. Our patients no. 21 through 26 with normal karyotypes constitute their group 1. Patients no. 18, 19, and 20 with relatively simple karyotypes constitute their group 2. Our remaining 17 patients with complex karyotypes constitute group 3. The patients studied by Nakamura5 and by Cuneo et aI6 can also be assigned to one of these groups. However, as previously noted, we could find no significant differences between groups 1 and 2.
Cuneo et aI6 previously suggested that a morphologic distinction could be made among M6 patients and that there was a correlation with karyotype. In our study, all patients had significant marrow dysplasia, although of variable degree (Table 2 ). However, we did not find any correlation between the degree of maturation or atypia of the erythroid precursors and the cytogenetic findings or prognosis; nor was there any correlation between the number of myeloblasts present and the cytogenetic findings or clinical outcome. More than half of the patients in the report of Cuneo et a16 had either evolved from a myelodysplastic disorder or had had prior cytotoxic treatment, whereas only 7 of the 26 patients in our study had any preleukemic phase, and none was previously treated with chemotherapy or radiation. This could explain some of the differences between the two reports.
Our observations on the regions of specific chromosomes that are frequently deleted in M6 patients and other patients with a del(5q) provide the type of clues used by others to identify tumor suppressor genes. The biologic role of the other chromosomal aberrations in these patients is unknown. Additional cytogenetic abnormalities that have been observed in AML de novo and t-AML/t-MDS were also seen in some of our patients with M6.1° These include trisomy 8 and partial monosomy for 12pll-p13, 16q12-q24, 17p, and 20q. Deletions of the long arm of chromosome 20 in myeloid disorders are interstitial in nature and include the region between q l l and q13. We assume that the loss of 17p involves the TP53 locus.21 Rearrangement of the TP53 gene has been reported in M6 cells transformed by Friend virus. 22 The recurring involvement of the short arm of chromosome 12 and the long arm of chromosome 16 could also be of importance, although no obvious candidate genes are presently available for investigation. Similar karyotypic clues were used by Vogelstein et a123 and others to search for and then to clone genes involved in the evolution of the malignant phenotype in colon cancer. It is conceivable that the progressive accumulation of all of these genetic alterations is important for disease progression in M6.
Our This finding parallels our observation of a good remission induction rate but short durations of remission and survival for patients with t-AML, most of whom also have abnormalities of chromosomes 5 and/or 7.*O3
The differences between primary MDS and M6 are not very distinct. There is a great deal of clinical, morphologic, and cytogenetic overlap, especially when one considers those patients with refractory anemia with excess of blasts ( > 5% blasts in the marrow). Previous studies have suggested that MDS patients with a chromosomally abnormal clone were at increased risk for rapid progression to acute For personal use only. on August 30, 2017. by guest www.bloodjournal.org From leukemia and early death as compared with patients with a normal k a r y~t y p e .~~,~~ More recent investigations have begun to modify this conclusion by showing that the increased risk is associated primarily with clones that have multiple chromosomal abnormalities or have a single abnormality involving loss of chromosome 7 or 7q.26, 27 In the present study, we have shown that once a patient fulfills the FAB criteria for M6, the percentage of blast cells did not correlate with survival in the subset of patients with chromosomal abnormalities of 5 and/or 7. This important observation supports the validity of the FAB criteria for M6 in that patients in whom myeloblasts may account for a small proportion of the total marrow elements still have a disease that behaves in an aggressive fashion. It will be important to correlate survival with the percentage of blasts cells in the smaller number of patients with primary MDS who have complex karyotypes and abnormalities of chromosomes 5 and/or 7. We predict that if the latter genetic changes are present, the disease will reflect the typical rapidly fatal course of M6 rather than that of a primary MDS.
Our analysis of the data in this study and others' reports leads us to the following conclusions. The FAB criteria for the diagnosis of M6 should be used in conjunction with cytogenetics at diagnosis to identify two subgroups of patients with different outcomes. Although the poor-risk group of M6 de novo who have abnormalities of chromosomes 5 and/or 7 have close similarities with erythroleukemia that occurs after cytotoxic treatment, for the time being, these two groups should be reported on separately until the causative events for M6 de novo and t-AML are known. Although CR rates are good for M6 de novo, remission duration has been short using conventional consolidation regimens for patients with abnormalities of chromosomes 5 andlor 7. Thus, these patients may benefit from allogeneic BM transplantation or experimental treatment in first remission. On the other hand, M6 patients with a more favorable cytogenetic pattern may do well with conventional chemotherapy treatment.
